NBW Capital LLC Decreases Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

NBW Capital LLC cut its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 86,615 shares of the company’s stock after selling 1,033 shares during the quarter. NBW Capital LLC’s holdings in HealthEquity were worth $5,743,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HQY. Mackenzie Financial Corp increased its holdings in shares of HealthEquity by 58.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock valued at $119,831,000 after purchasing an additional 664,979 shares during the period. Comerica Bank increased its holdings in shares of HealthEquity by 82,280.3% in the third quarter. Comerica Bank now owns 58,490 shares of the company’s stock valued at $4,273,000 after purchasing an additional 58,419 shares during the period. Natixis Advisors L.P. increased its holdings in shares of HealthEquity by 7.2% in the third quarter. Natixis Advisors L.P. now owns 17,664 shares of the company’s stock valued at $1,290,000 after purchasing an additional 1,180 shares during the period. Gotham Asset Management LLC acquired a new position in shares of HealthEquity in the third quarter valued at about $1,103,000. Finally, Loomis Sayles & Co. L P increased its holdings in shares of HealthEquity by 57.8% in the third quarter. Loomis Sayles & Co. L P now owns 399,683 shares of the company’s stock valued at $29,197,000 after purchasing an additional 146,372 shares during the period. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Delano Ladd sold 2,558 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now owns 47,438 shares in the company, valued at $3,917,904.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the transaction, the director now owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 2,558 shares of HealthEquity stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now owns 47,438 shares in the company, valued at approximately $3,917,904.42. The disclosure for this sale can be found here. Insiders have sold a total of 71,322 shares of company stock worth $5,682,895 over the last quarter. 2.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HQY. JPMorgan Chase & Co. increased their price objective on HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Barrington Research reaffirmed an “outperform” rating and set a $100.00 target price on shares of HealthEquity in a report on Friday, March 22nd. Barclays raised their target price on HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Bank of America raised their target price on HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Finally, JMP Securities assumed coverage on HealthEquity in a report on Thursday, April 4th. They set a “mkt outperform” rating and a $101.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.17.

HealthEquity Price Performance

HQY traded up $1.03 during trading on Thursday, hitting $80.90. The company’s stock had a trading volume of 188,400 shares, compared to its average volume of 600,709. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. HealthEquity, Inc. has a twelve month low of $48.86 and a twelve month high of $84.49. The business’s fifty day simple moving average is $81.02 and its 200 day simple moving average is $74.17. The firm has a market capitalization of $6.94 billion, a price-to-earnings ratio of 127.03, a P/E/G ratio of 1.31 and a beta of 0.53.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.08. The business had revenue of $262.39 million for the quarter, compared to the consensus estimate of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. On average, equities research analysts forecast that HealthEquity, Inc. will post 2.12 EPS for the current fiscal year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.